3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
7
Recurrence
3
Neoplasms
2
Melanoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pre-menopausal Breast Cancer
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Meningioma
1
Kidney Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ductal, Breast
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced and Selected Solid Tumors
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced Solid Tumor
1
Acrocephalosyndactylia
1
3rd Line GIST
1
Interventions
pembrolizumab
24
Paclitaxel
20
Carboplatin
19
Taxes
7
temsirolimus
6
Trastuzumab
6
Topotecan
5
Radiotherapy
5
Cisplatin
5
atezolizumab
4
Specimen Handling
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Gemcitabine
4
Docetaxel
4
Biopsy
4
Bevacizumab
4
olaparib
3
lenvatinib
3
dostarlimab
3
Sirolimus
3
Pemetrexed
3
Irinotecan
3
Interleukin-12 Subunit p35
3
Fulvestrant
3
Cetuximab
3
Albumin-Bound Paclitaxel
3
spartalizumab
2
gedatolisib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Endometrial Neoplasms
×
Alpelisib
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled